Drug Accountability refers to the complete documentation and tracking of investigational medicinal products in clinical trials \u2013 from manufacture and delivery to the investigational site, through dispensing to the trial participant, to the disposal of unused stock at the end of the trial. It is a central element of Good Clinical Practice and is firmly established, both regulatorily in ICH E6(R2) and in Regulation (EU) 536\/2014. Without complete and traceable documentation, neither patient safety nor the data integrity of a clinical trial can be adequately assured. Authorities such as the EMA and FDA place particular emphasis on this documentation during inspections.<\/p>\n
ICH E6(R2) requires the sponsor to implement suitable systems for tracking investigational medicinal products and to ensure that the location and quantity of every batch are known at all times. Article 51 of Regulation (EU) 536\/2014 stipulates that investigational medicinal products used in clinical trials must comply with Good Manufacturing Practice requirements \u2013 including complete documentation of all product movements. In addition, national medicines legislation, in Germany the Arzneimittelgesetz, governs the specific requirements for storage, dispensing and return at the investigational site.<\/p>\n
Under GCP, responsibility for Drug Accountability lies with the investigator or the investigational site. In practice, however, day-to-day performance is generally delegated to the Study Coordinator or to specially trained nursing staff. The sponsor \u2013 or the CRO engaged by the sponsor \u2013 is obliged to oversee compliance as part of clinical monitoring and to document all relevant records in the Trial Master File.<\/p>\n
A complete Drug Accountability Log records, at a minimum, the following information for each batch and each unit of the investigational medicinal product. For delivery to the investigational site, this includes the date, quantity delivered, batch number, expiry date and the condition on receipt. For storage, compliance with the prescribed temperature conditions and access restricted to authorised personnel only are recorded. Dispensing to trial participants includes the date, quantity dispensed, participant ID and the identity of the dispensing staff member. Finally, the return of unused units and complete documentation of disposal or return to the sponsor are recorded.<\/p>\n
Reconciliation of quantities \u2013 that is, the comparison between quantities delivered, dispensed, returned and disposed of \u2013 is the core component of the log. Any discrepancy must be explained and documented in writing. In blinded trials, the accountability procedure requires particular care so that blinding is not inadvertently broken. The records are archived in the Trial Master File after trial completion and must remain accessible for the statutory retention periods.<\/p>\n
Drug Accountability is a mandatory component of every monitoring visit, whether the Site Initiation Visit, a routine monitoring visit, or the Site Close-out Visit. The clinical monitor checks whether the documented quantities match the actual stock held at the investigational site. Discrepancies must be explained promptly, documented, and, where applicable, reported as a protocol deviation.<\/p>\n
Under Risk-Based Monitoring, the intensity of checks can be adapted to the individual risk profile of the investigational site. Sites with a good track record may be visited in person less frequently where a robust remote monitoring system is in place. Nevertheless, a visual check of physical stock at least once per trial generally remains obligatory.<\/p>\n
Incomplete Drug Accountability can have serious consequences. If a participant receives the wrong dose, an expired batch, or an incorrectly stored investigational product, their safety is directly jeopardised. At the same time, faulty documentation undermines the trial’s data integrity, because exposure data become unreliable and efficacy and safety analyses may be distorted.<\/p>\n
Regulators \u2013 including the EMA, FDA and national authorities such as the Paul-Ehrlich-Institut \u2013 scrutinise Drug Accountability records particularly closely during inspections. Deficiencies in this area regularly lead to Critical Findings and can result in a re-inspection or the exclusion of data from the marketing authorisation assessment.<\/p>\n
Who is responsible for Drug Accountability at the investigational site?<\/strong><\/p>\n Formally, responsibility lies with the investigator (Principal Investigator). In practice, they delegate it to trained personnel at the site, for example the Study Coordinator or the study nursing team. However, the investigator remains responsible for the correct conduct and completeness of the documentation.<\/p>\n What happens to unused investigational medicinal product after trial completion?<\/strong><\/p>\n Depending on the sponsor’s requirements, unused stock is either returned to the sponsor or destroyed on site. In both cases, the quantity, date and method must be fully documented. The Drug Accountability Log is then archived in the Trial Master File.<\/p>\n Must Drug Accountability also be maintained for non-interventional trials?<\/strong><\/p>\n For non-interventional trials, in which the medicinal product is prescribed as part of routine care, the strict GCP requirements for Drug Accountability generally do not apply. However, national requirements on medicines documentation and any sponsor-specific requirements set out in the study plan continue to apply.<\/p>\n","protected":false},"excerpt":{"rendered":" Drug Accountability refers to the complete documentation and tracking of investigational medicinal products in clinical trials \u2013 from manufacture and delivery to the investigational site, through dispensing to the trial participant, to the disposal of unused stock at the end of the trial. It is a central element of Good Clinical Practice and is firmly […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[],"class_list":["post-7027","glossary","type-glossary","status-publish","hentry"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/7027","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":1,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/7027\/revisions"}],"predecessor-version":[{"id":7029,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/7027\/revisions\/7029"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=7027"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=7027"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}